CM
ALXN

Columbus Macro’s Alexion Pharmaceuticals ALXN Stock Holding History

Columbus Macro’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,491
Closed -$458K – 175
2021
Q2 		$458K Sell
2,491
-50
-2% -$8.58K 0.14% 125
2021
Q1 		$389K Sell
2,541
-1,026
-29% -$159K 0.12% 133
2020
Q4 		$557K Sell
3,567
-591
-14% -$75.9K 0.17% 104
2020
Q3 		$476K Sell
4,158
-652
-14% -$70.3K 0.15% 106
2020
Q2 		$540K Sell
4,810
-1,210
-20% -$128K 0.15% 86
2020
Q1 		$541K Buy
6,020
+2,632
+78% +$258K 0.16% 103
2019
Q4 		$366K Buy
+3,388
New +$362K 0.08% 146

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Columbus Macro's ALXN Position: Q3 2021 in Review

Columbus Macro sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,491 shares — an estimated $458K sold.

Columbus Macro first reported a position in ALXN in Q4 2019 and held it in 7 quarters. The position peaked at $557K in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Columbus Macro reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Columbus Macro sold 2,491 Alexion Pharmaceuticals shares in Q3 2021, an estimated $458K.
  • Columbus Macro first reported a position in Alexion Pharmaceuticals in Q4 2019 and held it in 7 quarters.
  • Columbus Macro's Alexion Pharmaceuticals position peaked at $557K in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Columbus Macro's 13F filing for Q3 2021, filed 22 Oct 2021.